Michelle Gilson
Stock Analyst at Morgan Stanley
(1.16)
# 3,511
Out of 4,749 analysts
31
Total ratings
32.14%
Success rate
-5.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Upgrades: Overweight | $10 → $20 | $10.40 | +92.31% | 4 | Jan 9, 2025 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $66.92 | -55.17% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $5.25 | +223.81% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $130.66 | +50.01% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $20.46 | +119.94% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $11.48 | +562.02% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $63.36 | +43.62% | 12 | Mar 1, 2021 |
Vir Biotechnology
Jan 9, 2025
Upgrades: Overweight
Price Target: $10 → $20
Current: $10.40
Upside: +92.31%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $66.92
Upside: -55.17%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $5.25
Upside: +223.81%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $130.66
Upside: +50.01%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $20.46
Upside: +119.94%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $11.48
Upside: +562.02%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $63.36
Upside: +43.62%